[Click e-Stock] This Stock to Become a "Game Changer" in the Remote Patient Monitoring Market

Remote Patient Monitoring Adoption Rate at 3%
Expansion Through Strategic Partnerships With Major Shareholders

There are projections that Meju, a medical device specialist, is entering a phase of structural growth, driven by the expansion of the remote monitoring market and strategic partnerships with major investors.

On May 12, Lee Soo Jung, a researcher at IBK Investment & Securities, stated in a report titled "Growth Opportunities Captured Amid Hospital Digital Transformation" that "the company's performance improvement will begin in earnest this year."

First, Meju is drawing attention as a beneficiary of the burgeoning remote patient monitoring market. Meju has independently developed the HiCardi series, a wearable patch-type patient monitoring device that serves as a key product for ambulatory remote patient monitoring (aRPM) within hospitals. This enables real-time monitoring not only of patients in beds but also of those moving within the hospital. Researcher Kim noted, "With the increasing number of chronic disease patients due to an aging population and the shortage of medical personnel, demand for aRPM solutions is expected to surge." He added, "Currently, the adoption rate of digital patient monitoring in Korea stands at around 3%, so structural growth can be anticipated as this rate increases."

The next-generation product poised to increase Meju's market share in Korea's remote monitoring sector is the HiCardi 350. This device measures various vital signs, such as blood pressure and electrocardiograms, with a single patch, and its wireless-based monitoring capabilities are expected to improve work efficiency for medical staff. Researcher Jung analyzed, "As the number of measurable items eligible for reimbursement increases, revenue per patient will rise, and the growth foundation for platform sales will be strengthened as more devices are installed."

On the 26th, at the Korea Exchange in Yeongdeungpo-gu, Seoul, officials are taking a commemorative photo after presenting the listing commemorative plaque at the Meju KOSDAQ market listing ceremony. Photo by Yonhap News Agency

Meju is evaluated as having entered the initial stage of clear revenue growth and profitability improvement in last year's performance results. In 2025, sales amounted to 7.38 billion won, up by 5.01 billion won compared to the previous year. The cost of goods sold ratio dropped from 50.7% in 2024 to 31.6% last year, leading to improved profitability. Although the company recorded an operating loss of 2.83 billion won last year, the loss is on a declining trend.

Amidst this trend, collaboration with Dong-A ST is acting as a growth driver in Korea. In July 2022, Meju signed a strategic distribution partnership agreement with Dong-A ST for the domestic rights to HiCardi. Dong-A ST is a major shareholder, holding a 3.8% stake in Meju. Researcher Jung explained, "With a revenue structure that combines device sales to Dong-A ST and a subscription-based model, sales are expected to increase along with the cumulative expansion of device installations."

Meju is also expanding internationally. Researcher Jung pointed out, "Meju has secured global regulatory approvals, including from the U.S. Food and Drug Administration (FDA), and is working to expand exports through local distribution partners in 17 countries." He added, "Based on its domestic references, Meju is increasing its credibility with overseas hospitals, so export sales are also expected to rise."

This content was produced with the assistance of AI translation services.